Shionogi to acquire IntraBio in deal worth $2bn
The deal will expand Shionogi’s growing portfolio with IntraBio’s rare diseases capabilities
Read More
The deal will expand Shionogi’s growing portfolio with IntraBio’s rare diseases capabilities
Read MoreOct 5, 2026 | Healthcare, News
The new global awareness initiative calls for greater recognition, understanding and support for people living with chronic hand eczema
Read MoreOct 2, 2026 | News
Up to 91% of patients achieved at least 75% improvement in eczema severity and up to 67% achieved near-complete skin clearance
Read MoreOct 1, 2026 | News
Tulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in HS
Read MoreSep 30, 2026 | News, Regulatory
If approved, this treatment would offer a new option for the nearly one million Americans living with MS
Read MoreSep 29, 2026 | News, Regulatory
Desmoid tumours are rare soft tissue tumours that can grow aggressively into nearby tissues
Read MoreSep 28, 2026 | News, Regulatory
Treatment with Olumiant resulted in substantial scalp hair regrowth, as well as improvements in eyebrows and eyelashes
Read MoreSep 25, 2026 | News, Regulatory
The treatment is for adults in combination with atezolizumab
Read MoreThe deal focuses on addressing critical unmet medical needs
Read MoreSep 23, 2026 | News, Regulatory
Trixeo is the first and only triple-combination therapy approved in the EU for patients 12 years and older, independent of exacerbation history
Read MoreSep 22, 2026 | News, Healthcare
The partnership introduces a world-first flu vaccine and extends the health security pandemic agreement
Read MoreThe Board will advise Galimedix on scientific and clinical strategy
Read More
